Optimize autoimmune therapy market insightswith Real-World Data.
AstraZeneca’s advancements in inflammatory and autoimmune treatments are promising, with recent FDA approvals and ongoing clinical developments. Real-world evidence is essential for maximizing therapy impact, improving patient outcomes, and strengthening market position.
ContactLynx.MD supports these initiatives with an extensive platform of over 175 million real-world patient records, offering both structured and unstructured data beyond traditional clinical trials.
Real-World Insights
Understand treatment adherence, patient outcomes, and disease progression in real-time.
Patient Care Optimization
Identify factors affecting medication adherence and develop targeted interventions.
Market Expansion
Discover new patient populations to increase market share and revenue.
Data-Driven Decisions
Use real-world evidence to support post-marketing commitments and demonstrate long-term safety and efficacy.
Competitive Edge
Gain insights into competitor performance for informed decisions on pricing, promotion, and market positioning.
Structured and Unstructured Data
Unstructred Data
Healthcare Provider Notes:
- Free-text clinical notes, progress notes, discharge summaries.
- Handwritten or typed notes
- Dictated and transcribed notes
- Patient-reported outcomes (PROs): Quality of life, symptom burden.
Laboratory Reports:
- Comments and interpretations
- Image-based results (e.g., microscopy, pathology slides)
Medical Images
- Images, X-rays, MRIs, CT scans, ultrasounds
- Radiologist reports
Videos
- Surgical procedures
- Patient interviews
Pharmacovigilance Reports
- Medication prescription, adherence and changes
- Spontaneous adverse event reports (free-text descriptions)
- Case narratives
Structured Data
Patient-Level Data:
- Demographics: Age, gender, race, ethnicity, geographic location.
- Medical history: Comorbidities, previous treatments, allergies.
- Treatment information: Dosage, duration, adherence, route of administration.
- Outcomes: Efficacy measures, adverse events, hospitalizations, mortality.
- Laboratory results: Blood tests, imaging studies, biomarkers.
Provider Data
- Prescribing patterns: Drug utilization, patient demographics.
- Adverse event reporting: Frequency, severity, causality.
- Patient feedback: Treatment satisfaction, adherence challenges.
Claims Data
- Diagnosis codes: ICD-9/10/11 codes.
- Procedure codes: CPT/HCPCS codes.
- Drug claims: Prescriptions, refills, costs.
- Healthcare utilization: Inpatient, outpatient, emergency room visits.
Beyond autoimmune disease.
Whether your focus is Lupus, inflammatory GI disease, Eosinophilic Granulomatosis with Polyangiitis (EGPA), or Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP), Lynx.MD’s data extends to a broad range of autoimmune conditions. Additionally, the platform offers insights into respiratory diseases with autoimmune components, such as asthma and COPD.
Lynx.MD goes beyond the diagnosis code and structured EHR fields to understand patient experiences with therapeutics.
We delve into the lived experiences of patients, uncovering barriers to adoption and informing strategies to maximize therapy effectiveness.
Contact us today to discuss a personalized solution for AstraZeneca. Together, we can revolutionize the future of autoimmune treatment